NorthSea Therapeutics
Seedtable Score
56
Startups
3
Funding Rounds
4
Investors
$146.99m
Money raised
Overview
NorthSea Therapeutics, based in Amsterdam, shows promise in the specialized field of treating inflammatory, metabolic, and liver diseases with innovative therapeutic drugs. Their focus on novel treatments addresses a significant market gap where conventional pharmaceuticals and lifestyle changes often fall short. Supported by investors like Sofinnova Partners, Novo A/S, Forbion Capital Partners, and Ysios Capital, the company is well-positioned to develop and commercialize groundbreaking therapies. Their B2B model allows for efficient collaboration with healthcare providers and biotech firms, potentially leading to rapid market adoption and sustained growth.
- Website: https://northseatherapeutics.com
- Business model: b2b
- Company size: 11 - 51 employees
- Headquarters: Amsterdam, Netherlands
- Founded: 2017
- Social accounts: Linkedin
Unlock Complete Company Intelligence
Access comprehensive data and insights available only to Seedtable members
Financial Details
- • Complete funding history and valuations
- • Revenue estimates and financial metrics
- • Investment round details and terms
People & Contacts
- • Complete leadership team profiles
- • Contact information and email addresses
- • Board members and advisors
Market Intelligence
- • Competitive landscape analysis
- • Market position and growth metrics
- • Industry benchmarking data
Premium Tools
- • Export data and generate reports
- • Save companies to custom watchlists
- • API access for data integration
Join 10,000+ Professionals
Trusted by investors, founders, and analysts worldwide
Access detailed insights on 71,000+ companies worldwide
Investors (4)
Funding
Funding series
Funding Series Analysis
The company NorthSea Therapeutics has raised a total of $146.99m in funding over 3 rounds.
Key Insights:
- Series C: $80m
- Series B: $39.99m
- Series A: $27m
NorthSea Therapeutics Series A (2017, $27M)
$27m
NorthSea Therapeutics Series B (2020, $39M)
$39.99m
NorthSea Therapeutics Series C (2021, $80M)
$80m